Blood cells

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Retrieved on: 
Friday, July 9, 2021
Research, Stem cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Biology, Stem cells, Blood cells, Cell biology, Cancer immunotherapy, Biotechnology, Cell therapy, Acute myeloid leukemia, Immunotherapy, Hematopoietic stem cell, Haematopoiesis, Vor Biopharma, PureTech Health, VOR BIOPHARMA, PURETECH HEALTH

The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.

Key Points: 
  • The collaboration agreement provides that each company retains all rights and ownership to their respective programs and platforms.
  • We believe this unique combination will leverage each technologys strengths, while protecting patients against off-target effects of these powerful immunotherapies.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • Forward-looking statements in this press release include the Companys statements regarding its platforms potential to treat patients suffering from acute myeloid leukemia.

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Stem cells, Biology, Blood cells, Leukemia, Biotechnology, Cell biology, Cell therapy, Forward-looking statement, Acute myeloid leukemia, Myeloid tissue, Hematopoietic stem cell

An archived replay will also be available on the Company's website following the conference.

Key Points: 
  • An archived replay will also be available on the Company's website following the conference.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • This press release contains forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995.
  • Forward-looking statements in this press release include statements regarding Vors (the Company) platforms potential to treat patients suffering from acute myeloid leukemia.

Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System

Retrieved on: 
Tuesday, April 13, 2021
Branches of biology, Blood, Medical specialties, Blood cells, Hematology, Transfusion medicine, In science, Red blood cell, White blood cell

Blood center validations required for local adoption of the Hemanext ONE RBC Processing and Storage System were completed in Norway in 2020.

Key Points: 
  • Blood center validations required for local adoption of the Hemanext ONE RBC Processing and Storage System were completed in Norway in 2020.
  • Hemanext also plans to submit its De Novo request for marketing authorization from the U.S. Food and Drug Administration (FDA).\nThe Hemanext ONE RBC Processing and Storage System is CE Marked for the processing and storage of CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LRRBC) that have been prepared and processed with the HEMANEXT ONE system within 24-hours of collection.
  • "We will be eagerly awaiting the real-world results of Hemanext ONE when compared to conventionally-stored blood by our European colleagues.
  • It is CE-marked for the processing and storage of CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LRRBC) that have been prepared and processed with the HEMANEXT ONE system within 24-hours of collection.

Biotech EryPharm Announces a Revolutionary Technological Breakthrough in the Large- Scale Manufacturing of Red Blood Cells

Retrieved on: 
Thursday, April 8, 2021
Manufacturing, Other Health, Stem cells, Pharmaceutical, Surgery, General Health, Hospitals, Other Manufacturing, Cardiology, Biotechnology, Science, Other Science, Research, Health, Medical Supplies, Engineering, Branches of biology, Blood, Biology, Hematology, Transfusion medicine, Blood cells, Stem cells, Hematopoietic stem cell, Red blood cell, Blood transfusion, Blood donation, Haematopoiesis

EryPharm, startup created in 2016, has achieved a revolutionary technological breakthrough to mass-produce cultured red blood cells to develop new sourcing for blood transfusion.

Key Points: 
  • EryPharm, startup created in 2016, has achieved a revolutionary technological breakthrough to mass-produce cultured red blood cells to develop new sourcing for blood transfusion.
  • Supporting and complementing regular blood donation, this medical product will improve the quality of life of multi-transfused patients who suffer from hereditary or acquired diseases of the red blood cells in particular.
  • After four years of Research and Development, EryPharm is now entering a pilot production phase and scale-up of Cultured Red Blood Cells (cRBC) using Hematopoietic Stem Cells (HSC).
  • HSC can be stored in the long-term, ensuring sustained visibility of red blood cells when needed.

MD Anderson Cancer Center Publication Shows How Bionano’s Saphyr System Can Significantly Reduce Time to Actionable Results for Myelodysplastic Syndrome Patients

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Anatomy, Medical specialties, Blood cells, Acute myeloid leukemia, Bone marrow, Leukemia, Myeloid tissue, Myelodysplastic syndrome, Chronic myelomonocytic leukemia

MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.

Key Points: 
  • MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.
  • Several tests are run sequentially after initial data analysis to confirm gene-specific variants, leading to a diagnostic process that can span several weeks.
  • In this study, Dr. Kanagal-Shamanna evaluated the performance of OGM in a series of 12 previously well-characterized MDS cases using clinical bone marrow samples.
  • Erik Holmlin, PhD, CEO of Bionano Genomics, commented: The MD Anderson Cancer Center is one of the worlds most important cancer research and treatment centers.

ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium

Retrieved on: 
Tuesday, May 5, 2020
Life sciences, Branches of biology, Biology, Hematology, Blood cells, Blood, Red blood cell, Biopharmaceutical, Cancer

The EVIDENCE consortium, consisting of leading experts in the field of red blood cell research, will explore how red blood cells are influenced by their extra-cellular environment.

Key Points: 
  • The EVIDENCE consortium, consisting of leading experts in the field of red blood cell research, will explore how red blood cells are influenced by their extra-cellular environment.
  • The EVIDENCE consortium will investigate the behavior of red blood cells under physiological flow conditions, i.e.
  • The European Union has provided four million euros of funding for the EVIDENCE project as part of the Marie Skodowska-Curie Actions program.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.

Nuclear Factor Erythroid 2 Related Factor 2 - 2020 Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Health, Pharmaceutical, Branches of biology, Cell biology, Transcription factors, Blood cells, Nuclear factor erythroid 2-related factor 2, Erythropoietin receptor, Erythropoietin, Red blood cell

The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 39 molecules.
  • The report, Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review H1 2020 outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued projects.

Nuclear Factor Erythroid 2 Related Factor 2 Pipeline & Therapeutics Landscape, 2020

Retrieved on: 
Friday, April 3, 2020
Branches of biology, Cell biology, Transcription factors, Blood cells, Nuclear factor erythroid 2-related factor 2, Erythropoietin receptor, Erythropoietin, Red blood cell

DUBLIN, April 3, 2020 /PRNewswire/ -- The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 39 molecules.
  • The report, Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review H1 2020 outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 targeted therapeutics development with respective active and dormant or discontinued projects.

2020 Cell Surface Markers - US, Japan, Germany, Spain, France, Italy and the UK - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 5, 2020
Health, Genetics, Branches of biology, Medical specialties, Cell biology, Immune system, Lymphatic system, Immunology, Blood cells, Macrophage, Monocyte, Flow cytometry, Hybridoma technology, Lymphocyte

The "2020 Cell Surface Markers: US, Europe, Japan - Competitive Landscape, Country Segment Forecasts, Innovative technologies, latest Instrumentation, Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Cell Surface Markers: US, Europe, Japan - Competitive Landscape, Country Segment Forecasts, Innovative technologies, latest Instrumentation, Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells.
  • A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies.
  • During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.

BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting

Retrieved on: 
Monday, December 9, 2019
Branches of biology, Anatomy, Medical specialties, Stem cells, Hematopoiesis, Skeletal system, Blood cells, Histology, CD34, Hematopoietic stem cell, Bone marrow, Haematopoiesis

Following our previously presented data at ASH 2018, demonstrating evidence of bone marrow CD34+ mobilization with Plinabulin, we now have additional evidence of a bone marrow progenitor stem cell protective effect of Plinabulin as an important MoA for the prevention of CIN.

Key Points: 
  • Following our previously presented data at ASH 2018, demonstrating evidence of bone marrow CD34+ mobilization with Plinabulin, we now have additional evidence of a bone marrow progenitor stem cell protective effect of Plinabulin as an important MoA for the prevention of CIN.
  • This data is particularly intriguing, as Plinabulin appears to protect bone marrow stem cells without causing bone pain, said Dr. Douglas Blayney, the Principal Investigator of the CIN program with Plinabulin.
  • Our collective clinical trial dataset has provided strong evidence of Plinabulins potent ability to prevent CIN through protection from chemo-induced bone marrow suppression, and the data from our abstracts further our understanding of Plinabulins MoA for CIN.
  • Plinabulins CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice.